Ethan Oren Perlstein
CEO @ Perlara
San Francisco, United States
Ethan Oren Perlstein is a seed investor at Perlara in San Francisco focused on Biotechnology and Life Science. Over the course of the last decade, first as a graduate student at Harvard University in the Department of Molecular and Cell Biology with PhD advisor Professor Stuart Schreiber and then as an independent postdoctoral fellow at the Lewis-Sigler Institute at Princeton University, Dr. Ethan Perlstein developed an approach to studying old drugs anddiscovering new drugs in model organisms called evolutionary pharmacology. Ethan is an author on 19 peer-reviewed scholarly publications, including the discovery of a novel mechanism of action for the antidepressant Zoloft based on studies in yeast cells.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Ethan Oren Perlstein invests in
Stages Ethan Oren Perlstein invests in
Countries Ethan Oren Perlstein invests in
Investment Focus
Industry
- Biotechnology 4 (100%)
- Life Science 2 (50%)
- Cannabis 1 (25%)
- Biopharma 1 (25%)
- Cosmetics 1 (25%)
Country
- United States 3 (75%)
- Canada 1 (25%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
BluumBio
|
BluumBio develops cutting-edge bioremediation technologies and services, offering scalable solutions for companies of all sizes. BluumBio makes bacteria and plants eat toxic chemicals that clean up pollution. | Seed / Sep 16, 2021 | |
Promakhos Therapeutics
|
Promakhos Therapeutics is building a platform of bacterial molecules to awaken the human body’s innate ability to control inflammation and heal. | Seed / Sep 02, 2021 | |
Epinoma
|
Epinoma is a diagnostics company that focuses on the multi-omics approach to cancer monitoring. It engineers proteins that control the operating system of biology. The company was founded in 2020 and is headquartered in San Francisco, California. | $4.5M / Seed / Aug 22, 2021 | |
Hyasynth Bio
|
We’re a bioengineering company that's reducing the massive environmental footprint of the CBD market through precision fermentation. And our technology never touches a plant. CBD is a global $12Bn consumer market and Hyasynth's precision fermentation platform eliminates wasteful plant cultivation and decreases the carbon impact by morethan 97%. Hyasynth is the world's only bioengineering company with a scalable, fermentation process for CBD that is cost-efficient and regulatory-compliant. | Seed / Jun 29, 2015 |
Co-Investors
About Perlara
Perlara, PBC is the first Public Benefit Corporation accelerating precision drug discovery for 5,000+ rare genetic diseases. PLab uses a platform of CRISPR-engineered animal models (yeast, nematodes, fruit flies and zebrafish) in whole-organism phenotypic screens to generate disease-reversing orphan drug candidates much faster and cheaper thantraditional in vitro and cell-based approaches. Their lead discovery programs are Niemann-Pick Type C, a lysosomal storage disorder first described nearly a century ago, and NGLY1 Deficiency, a congenital disorder of glycosylation first diagnosed last year. Their initial pipeline includes, among others, additional lysosomal storage disorders, e.gs, Batten and Mucolipidosis IV, mitochondrial diseases, e.g., Leigh, and peroxisomal biogenesis disorders, e.g., Zellweger.
Perlara Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Nina DiPrimio
Director of Research and Development
|
|||
Richard Sachs
VP Creative Services
|
|||
2 more contacts available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Ethan Oren Perlstein invest in?
Ethan Oren Perlstein invests primarily in Biotechnology, Life Science and Cannabis startups, most often at Seed stage. Most of the 4 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Ethan Oren Perlstein last invest?
The most recent investment recorded for Ethan Oren Perlstein closed in Sep 2021. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
